Tuesday, 20 February 2018

Aimmune's peanut allergy drug meets main goal of key study

(Reuters) - U.S. drug developer Aimmune Therapeutics Inc said on Tuesday its peanut allergy drug met the main goal of an eagerly awaited late-stage study.


Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)